{"groups":[{"description":"Patients with morphological relapse for AML and MDS at least 90 days post-transplant.\n\nMDS patients: Re-appearance of dysplastic changes in the bone marrow, with or without increase in bone marrow blast count, which is pathologically consistent with myelodysplastic syndrome.\n\nAML patients:\n\nBone marrow blast count \\>/= 5%.","id":"FG000","title":"Cohort 1: Relapsed Leukemia Post-transplant"},{"description":"Cohort 2: Persistence or reappearance of minimal residual disease by flow cytometry or cytogenetic or molecular testing while being in morphological remission after allogeneic stem cell transplantation.","id":"FG001","title":"Cohort 2: MRD(Minimal Residual Disease) Post-transplant"},{"description":"Cohort 3: High risk AML and MDS patients who are in complete remission morphologically with no evidence of minimal residual disease by flow cytometry or cytogenetic or molecular testing after allogeneic stem cell transplantation.","id":"FG002","title":"Cohort 3: Maintenance Treatment Post-transplant"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}],"type":"Physician Decision"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"18"},{"groupId":"FG002","numSubjects":"24"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"17"},{"groupId":"FG002","numSubjects":"24"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"All participants were registered at MD Anderson Cancer Center."}